KPIs & Operating Metrics(New)
Growth Metrics

Johnson & Johnson (JNJ) Non Operating Income (2009 - 2026)

Johnson & Johnson recorded quarterly Non Operating Income of -$294.0 million in Q1 2026, up 39.13% quarter-over-quarter from -$483.0 million in Q4 2025, and down 104.02% year-over-year from $7.3 billion in Q1 2025.

Johnson & Johnson's Non Operating Income history runs 18 years deep, the most recent figure standing at -$294.0 million for Q1 2026.

  • In Q1 2026, Non Operating Income fell 104.02% year-over-year to -$294.0 million; the TTM figure through Mar 2026 stood at -$406.0 million (down 108.07% YoY), while the FY2025 annual figure was $7.2 billion, up 253.58% from the prior year.
  • Non Operating Income came in at -$294.0 million for Q1 2026 at Johnson & Johnson, up from -$483.0 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $7.3 billion in Q1 2025 to a low of -$6.9 billion in Q2 2023.
  • A 5-year average of -$302.4 million and a median of -$273.0 million in 2022 frame the typical range for Non Operating Income.
  • Across the five-year window, Non Operating Income plunged 6903.92% in 2023 and soared 404.53% in 2025, its largest moves.
  • Johnson & Johnson's Non Operating Income stood at -$226.0 million in 2022, then soared by 286.28% to $421.0 million in 2023, then tumbled by 61.76% to $161.0 million in 2024, then tumbled by 400.0% to -$483.0 million in 2025, then soared by 39.13% to -$294.0 million in 2026.
  • According to Business Quant data, Non Operating Income over the past three periods registered -$294.0 million, -$483.0 million, and $478.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Op. Inc. (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn -65.00 Mn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -294.00 Mn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -2.31 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -138.00 Mn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 75.00 Mn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 235.00 Mn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -861.00 Mn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -32.00 Mn
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 29, 2026 -294.00 Mn
Dec 28, 2025 -483.00 Mn
Sep 28, 2025 478.00 Mn
Jun 29, 2025 -107.00 Mn
Mar 30, 2025 7.32 Bn
Dec 29, 2024 161.00 Mn
Sep 29, 2024 -1.80 Bn
Jun 30, 2024 -653.00 Mn
Mar 31, 2024 -2.40 Bn
Dec 31, 2023 421.00 Mn
Oct 1, 2023 -499.00 Mn
Jul 2, 2023 384.00 Mn
Apr 2, 2023 -6.94 Bn
Jan 1, 2023 -330.00 Mn
Oct 2, 2022 -226.00 Mn
Jul 3, 2022 -273.00 Mn
Apr 3, 2022 102.00 Mn
Oct 3, 2021 -1.85 Bn
Jul 4, 2021 488.00 Mn
Apr 4, 2021 882.00 Mn
Jan 3, 2021 -2.35 Bn
Sep 27, 2020 -1.20 Bn
Jun 28, 2020 -24.00 Mn
Mar 29, 2020 679.00 Mn
Dec 29, 2019 -16.00 Mn
Sep 29, 2019 -4.21 Bn
Jun 30, 2019 1.68 Bn
Mar 31, 2019 300.00 Mn
Dec 30, 2018 -978.00 Mn
Sep 30, 2018 -3.00 Mn
Jul 1, 2018 -364.00 Mn
Apr 1, 2018 -60.00 Mn
Dec 31, 2017 53.00 Mn
Oct 1, 2017 297.00 Mn
Jul 2, 2017 -527.00 Mn
Apr 2, 2017 219.00 Mn
Jan 1, 2017 -1.07 Bn
Oct 2, 2016 54.00 Mn
Jul 3, 2016 -557.00 Mn
Apr 3, 2016 39.00 Mn
Sep 27, 2015 -420.00 Mn
Jun 28, 2015 931.00 Mn
Mar 29, 2015 348.00 Mn
Dec 28, 2014 -963.00 Mn
Sep 28, 2014 1.35 Bn
Jun 29, 2014 -226.00 Mn
Mar 30, 2014 -86.00 Mn
Dec 29, 2013 -868.00 Mn
Sep 29, 2013 -943.00 Mn
Jun 30, 2013 -172.00 Mn
Mar 31, 2013 -515.00 Mn
Dec 30, 2012 -319.00 Mn
Sep 30, 2012 90.00 Mn
Jul 1, 2012 -2.01 Bn
Apr 1, 2012 611.00 Mn
Jan 1, 2012 -4.61 Bn
Oct 2, 2011 308.00 Mn
Jul 3, 2011 -206.00 Mn
Apr 3, 2011 13.00 Mn
Oct 3, 2010 292.00 Mn
Jul 4, 2010 -18.00 Mn
Apr 4, 2010 1.59 Bn
Jan 3, 2010 361.00 Mn
Sep 27, 2009 96.00 Mn
Jun 28, 2009 6.00 Mn
Mar 29, 2009 75.00 Mn